| Pharmaceutical Information |
| Drug Name |
Aprotinin (bovine) |
| Drug ID |
BADD_D00158 |
| Description |
Aprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and liver surgery. For this use, it is typically administered by injection. The goal of using of aprotinin was subsequently to minimize end-organ damage resulting from hypotension due to blood loss in surgery and to reduce the necessity for blood transfusions during surgery. Nevertheless, the drug was formally withdrawn worldwide in May of 2008 after studies confirmed that its use enhanced the risk of complications or death. The substance is consequently made available only for very restricted research use. |
| Indications and Usage |
For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion. |
| Marketing Status |
approved; investigational; withdrawn |
| ATC Code |
B02AB01 |
| DrugBank ID |
DB06692
|
| KEGG ID |
D02971
|
| MeSH ID |
D007611
|
| PubChem ID |
16130295
|
| TTD Drug ID |
D08XYX
|
| NDC Product Code |
55463-0031 |
| UNII |
04XPW8C0FL
|
| Synonyms |
Aprotinin | Trypsin Inhibitor, Basic, Pancreatic | Bovine Kunitz Pancreatic Trypsin Inhibitor | BPTI, Basic Pancreatic Trypsin Inhibitor | Kallikrein-Trypsin Inactivator | Inactivator, Kallikrein-Trypsin | Kallikrein Trypsin Inactivator | Kunitz Pancreatic Trypsin Inhibitor | Trypsin Inhibitor, Kunitz, Pancreatic | Basic Pancreatic Trypsin Inhibitor | Bovine Pancreatic Trypsin Inhibitor | Pulmin | Traskolan | Dilmintal | Zymofren | Antilysin | Contrykal | Kontrykal | Kontrikal | Contrical | Iniprol | Trasylol |
|
| Chemical Information |
| Molecular Formula |
C284H432N84O79S7 |
| CAS Registry Number |
9050-74-2 |
| SMILES |
CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(
C(=O)NCC(=O)NC(C(=O)NC2CSSCC3C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)
NC(C(=O)N4CCCC4C(=O)N5CCCC5C(=O)NC(C(=O)NC(C(=O)NCC(=O)N6CCCC6C(=O)NC(CSSCC(C(=O
)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O
)NC(C(=O)NC(C(=O)N3)CC(=O)O)CCC(=O)O)C)CO)CCCCN)CC7=CC=CC=C7)CC(=O)N)CC(=O)N)CCC
NC(=N)N)CCCCN)C)CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C
(NC2=O)CCC(=O)N)C(C)O)CC8=CC=CC=C8)C(C)C)CC9=CC=C(C=C9)O)C(=O)NC(C(=O)NC(C(=O)NC
(C(=O)N1)CCCNC(=N)N)C)CCCCN)C(C)O)CC1=CC=C(C=C1)O)CCC(=O)O)CC(C)C)NC(=O)C(CC1=CC
=CC=C1)NC(=O)C(CC(=O)O)NC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)N)C(=O)NCC(=O)NCC(=O)NC(C)
C(=O)O)C(C)O)CCCNC(=N)N)CCSC)CC(C)C)C)CCCCN)C)CC(=O)N)CC1=CC=C(C=C1)O)CC1=CC=CC=
C1)CC1=CC=C(C=C1)O)CCCNC(=N)N)C(C)CC |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
